Navigation Links
3SBio Inc. Announces Second Quarter 2008 Results
Date:8/12/2008

SHENYANG, China, Aug. 12 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the second quarter ended June 30, 2008.

Second Quarter 2008 Financial Highlights:

-- Total net revenues increased 38.4% over the second quarter 2007 to

RMB59.6 million (US$8.7 million).

-- Net revenue from our flagship recombinant human erythropoietin

("EPO") products, marketed under our EPIAO brand, increased 23.7%

over the second quarter 2007 to RMB37.1 million (US$5.4 million).

-- Net revenue from our protein-based therapeutic recombinant human

thrombopoietin ("TPO") products, marketed under our TPIAO brand,

increased 66.9% over the second quarter 2007 to RMB16.1 million (US$2.3

million).

-- Operating income increased 10.5% over the second quarter 2007 to

RMB15.2 million (US$2.2 million).

-- Net income decreased 16.9% over the second quarter 2007 to RMB19.4

million (US$2.8 million).

-- Net income per American depositary share ("ADS") for the second

quarter 2008 was RMB0.89 (US$0.13) compared with RMB1.07 for the second

quarter 2007.

First Half 2008 Financial Highlights:

-- Total net revenues increased 46.7% over the first half of 2007 to

RMB115.0 million (US$16.8 million).

-- Net revenue from EPIAO increased 31.7% over the first half of 2007 to

RMB72.6 million (US$10.6 million).

-- Net revenue from TPIAO increased 83.2% over the first half of 2007 to

RMB31.5 million (US$4.6 milli
'/>"/>

SOURCE 3SBio Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
2. 3SBio Inc. to Hold Annual General Meeting
3. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
4. 3SBio Inc. To Present at the 19th Annual Piper Jaffray Health Care Conference
5. 3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
6. 3SBio Inc. to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. 3SBio Inc. Schedules 2007 Fourth Quarter and Full Year Earnings Release on Wednesday, February 20, 2008
8. 3SBio Inc. Announces Change to the Board of Directors
9. 3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results
10. 3SBio Inc. Announces Promotion of David Chen as Chief Operating Officer
11. 3SBio Inc. Approves Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)...  Caris Life Sciences® today announced the presentation ... utilized Caris Molecular Intelligence®, the company,s panomic, comprehensive ... in patients with colorectal and pancreatic cancer subtypes, ... protein 1 (PD-1) and its ligand, PD-L1. The ... American Society of Clinical Oncology Annual Meeting (ASCO) ...
(Date:5/29/2015)... SILVER SPRING, Md. and RESEARCH TRIANGLE ... Therapeutics Corporation (NASDAQ: UTHR ) announced today that ... United Therapeutics, will provide an overview and update on the ... New York City . The ... on Thursday, June 4, 2015, at 11:00 AM Eastern Time, ...
(Date:5/29/2015)... Translation is frequently listed as one of the ... used in a way that is right for a company, ... product or service offering. , Here are some of ... on a company's bottom line: , 1.    Attract bigger audience. , ... can use, why not offer it globally? Nelson Mandela once ...
(Date:5/28/2015)... , May 28, 2015  Quest Diagnostics Incorporated ... diagnostic information services, announced that it is scheduled to ... New York.  Steve Rusckowski , the company,s President ... five point strategy.  The presentation is scheduled for Tuesday, ... The presentation will be webcast live during the ...
Breaking Biology Technology:Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 2Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 3Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 4Three Ways Translation Can Help Businesses Grow 2Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference 2
... Calif., Aug. 28 GenVault Corporation, the,leader in ... Quebec and the Centre hospitalier affilie universitaire de,Chicoutimi ... Consortium. The,partnership included last week,s Dynamic Archive sale ... archiving and retrieving samples,that are contributed to the ...
... for successful completion of ... Phase 2b clinical trial -, ROCKVILLE, ... today announced that it will receive a $40,million payment from Novartis ... 2b trial of Albuferon(R) (albinterferon,alfa-2b) in treatment-naive patients with chronic hepatitis ...
... HIFU Revenue ... FY2007 Annual Targets Under Review, BEIJING, ... (Nasdaq: CMED ), a leading China-based,medical device company ... and high intensity focused ultrasound tumor,therapy system, today announced ...
Cached Biology Technology:GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product 2GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product 3GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product 4Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development 2Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development 3Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development 4China Medical Technologies Reports First Quarter Financial Results 2China Medical Technologies Reports First Quarter Financial Results 3China Medical Technologies Reports First Quarter Financial Results 4China Medical Technologies Reports First Quarter Financial Results 5China Medical Technologies Reports First Quarter Financial Results 6China Medical Technologies Reports First Quarter Financial Results 7China Medical Technologies Reports First Quarter Financial Results 8China Medical Technologies Reports First Quarter Financial Results 9China Medical Technologies Reports First Quarter Financial Results 10China Medical Technologies Reports First Quarter Financial Results 11China Medical Technologies Reports First Quarter Financial Results 12China Medical Technologies Reports First Quarter Financial Results 13China Medical Technologies Reports First Quarter Financial Results 14
(Date:5/29/2015)... DUBLIN , May 28, 2015 ... the addition of the "Facial Recognition Market ... User - Global Forecast to 2020" report ... years, have seen facial recognition technology become more ... technology to gain traction and investment from the ...
(Date:5/28/2015)... May 28, 2015 Industry analyst firm ... new report titled "Markets for Self-Healing Materials: 2015-2022." According ... capsule and vascular systems, biomaterials, relevant shape memory ... around $2.7 billion by 2020. The ... coverage of smart materials. Other recent n-tech reports have ...
(Date:5/27/2015)...   Codonics (codonics.com), a global ... documentation solutions and Omnicell  (omnicell.com), a ... is pleased to announce their state of ... System® (SLS), an award-winning FDA class 2 ... Anesthesia Workstation, helps prevent medication errors, streamlines ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... costs associated with storing nuclear waste and the possibility ... they may no longer be obstacles on the road ... at the University of Notre Dame, led by Thomas ... and concurrent professor of chemistry and biochemistry, showcases Notre ...
... the University of Melbourne have identified a new way ... hoped the test would be more cost effective and ... allergy in the community. Currently, an ... allergy, and while an oral food challenge is definitive ...
... A personality profile marked by overly gregarious yet anxious ... buried deep in the front center of the brain, say ... different types of brain imaging to pinpoint the suspect brain ... characterized by these behaviors. Matching the scans to scores ...
Cached Biology News:New paper by Notre Dame researchers describes method for cleaning up nuclear waste 2Test to improve peanut allergy diagnosis 2Friendly to a fault, yet tense: Personality traits traced in brain 2Friendly to a fault, yet tense: Personality traits traced in brain 3
One bottle containing 30 ml of protein solution and 0.1% sodium azide....
No description available in Ensembl Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Used in May-Grunwald Giemsa stain....
Sheep polyclonal to Quinolone ( Abpromise for all tested applications). Antigen: Norfloxacin(N)conjugated to BSA...
Biology Products: